Back to top

vaccines: Archive

Zacks Equity Research

Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.

SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change

Sundeep Ganoria

Moderna Stock Falls 20% in a Month: Time to Sell or Hold?

Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.

GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change

Zacks Equity Research

ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty

Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.

PFEPositive Net Change MRNAPositive Net Change ARCTPositive Net Change BNTXPositive Net Change

Zacks Equity Research

GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.

GSKPositive Net Change ILMNPositive Net Change KRYSPositive Net Change BVSPositive Net Change

Andrew Rocco

Why Novavax is Gaining Ground in COVID-19 Vaccine Race

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.

SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change

Zacks Equity Research

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

SNYPositive Net Change GSKPositive Net Change MRKPositive Net Change MRNAPositive Net Change